--- title: "EDAP TMS | 10-Q: FY2026 Q1 Revenue: USD 17.81 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285608363.md" datetime: "2026-05-07T20:09:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285608363.md) - [en](https://longbridge.com/en/news/285608363.md) - [zh-HK](https://longbridge.com/zh-HK/news/285608363.md) --- # EDAP TMS | 10-Q: FY2026 Q1 Revenue: USD 17.81 M Revenue: As of FY2026 Q1, the actual value is USD 17.81 M. EPS: As of FY2026 Q1, the actual value is USD -0.24. EBIT: As of FY2026 Q1, the actual value is USD -7.019 M. #### Overall Financial Performance EDAP TMS S.A.’s total revenues increased by 24.8%, from $14.3 million in the three months ended March 31, 2025, to $17.8 million in the three months ended March 31, 2026 . The company recorded a consolidated net loss of - $9.1 million in the three months ended March 31, 2026, compared to a net loss of - $7.4 million in the same period of 2025 . #### Gross Profit and Operating Expenses Gross profit increased to $8.1 million in the three months ended March 31, 2026, from $6.0 million in the prior year period . The gross margin improved to 45.73% for the three months ended March 31, 2026, up from 42.01% in the corresponding period of 2025 . Total operating expenses increased by 26%, or $3.2 million, reaching $15.5 million in the three months ended March 31, 2026, compared to $12.3 million in the prior year . Research and Development (R&D) expenses remained flat at $2.6 million in both the three months ended March 31, 2026, and 2025 . Selling and Marketing expenses were $7.1 million in the three months ended March 31, 2026, compared to $6.1 million in the same period of 2025 . General and Administrative expenses increased by 58.5%, or $3.7 million, to $5.8 million in the three months ended March 31, 2026 . Loss from operations was - $7.4 million for the three months ended March 31, 2026, compared to - $6.3 million for the same period in 2025 . #### Financial Items Net financial expense was - $1.714 million in the three months ended March 31, 2026, primarily driven by a - $1.3 million variation in the fair value of EIB warrants and - $0.4 million in EIB loan interest expense . This contrasts with a net financial income of $15 thousand in the three months ended March 31, 2025 . A net foreign currency exchange gain of $142 thousand was recorded in the three months ended March 31, 2026, compared to a loss of - $1.0 million in the prior year period . Income tax expenses remained relatively flat at - $145 thousand in the three months ended March 31, 2026, and - $144 thousand in the three months ended March 31, 2025 . #### Segment Performance ##### HIFU Division Total revenues increased by 78.3%, from $6.5 million in Q1 2025 to $11.6 million in Q1 2026 . Sales of medical devices increased by 146.7%, reaching $6.4 million in Q1 2026 (11 Focal One units sold, including 5 in the U.S.), up from $2.6 million in Q1 2025 (6 Focal One units sold, including 2 in the U.S.) . Treatment-driven revenue increased by 30.5% to $4.5 million in Q1 2026, from $3.4 million in Q1 2025 . Sales of HIFU maintenance services increased by 50.1% to $0.7 million in Q1 2026, from $0.5 million in Q1 2025 . Operating loss for the HIFU division was - $5.9 million in Q1 2026, compared to - $5.6 million in Q1 2025 . ##### ESWL Division Total revenues decreased by 15.8%, from $1.8 million in Q1 2025 to $1.5 million in Q1 2026 . Sales of ESWL-related consumables, spare parts, RPP, leasing, and services decreased by 11.4%, from $1.6 million in Q1 2025 to $1.4 million in Q1 2026 . Operating income for the ESWL division was $0.3 million in Q1 2026, compared to $0.5 million in Q1 2025 . ##### Distribution Division Total revenues decreased by 21.2%, from $5.9 million in Q1 2025 to $4.7 million in Q1 2026 . Sales of medical devices decreased by 44.9%, from $3.2 million in Q1 2025 to $1.8 million in Q1 2026 . Sales of Distribution-related consumables, spare parts, leasing, and services increased by 6.6%, from $2.7 million in Q1 2025 to $2.9 million in Q1 2026 . Operating income for the Distribution division was $0.2 million in Q1 2026, compared to an operating loss of - $0.2 million in Q1 2025 . #### Cash Flow Net cash used in operating activities for the three months ended March 31, 2026, was - $3.0 million . Net cash used in investing activities was - $0.8 million, primarily due to - $0.4 million in capitalized assets and - $0.5 million in property and equipment . Net cash used in financing activities was - $1.4 million, mainly from the repayment of - $0.7 million in long-term borrowings and financing leases, and a - $0.7 million reduction in short-term borrowings . Cash and cash equivalents decreased from $20.452 million at the beginning of the year to $15.012 million at the end of March 31, 2026 . #### Future Outlook and Strategy EDAP TMS S.A. is shifting its growth strategy to focus on its core proprietary HIFU activities, de-emphasizing its non-HIFU Distribution and ESWL businesses . The company believes it has sufficient funds for at least twelve months following an April 2026 EIB credit facility disbursement . However, EDAP TMS S.A. may need to raise substantial additional financing to meet future cash flow needs until profitability is achieved, and management is exploring various funding and restructuring options . ### Related Stocks - [EDAP.US](https://longbridge.com/en/quote/EDAP.US.md) ## Related News & Research - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [FRONTERA ANNOUNCES FIRST QUARTER 2026 RESULTS | FECCF Stock News](https://longbridge.com/en/news/286507909.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Elkem updates financial calendar for 2026 reporting schedule](https://longbridge.com/en/news/286917298.md)